Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody - ScienceDirect
Biomolecules | Free Full-Text | Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors | HTML
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction - ScienceDirect
KAPAG collection – KAPAG Board + Paper
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: | BTT
GD2 - Wikipedia
FC FOODCART / GD2 / MM Frohnleiten GmbH - MM digital - Product Details
Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors | Cancer Gene Therapy
Baden Karton Products | badenboard.com
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: | BTT
Frontiers | Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy - ScienceDirect
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma | Journal of Hematology & Oncology | Full Text
Chromoduplexkarton GD2: recycelter Faltschachtelkarton | Labelprint24
ASC amino acid transporter 2, defined by enzyme‐mediated activation of radical sources, enhances malignancy of GD2‐positive small‐cell lung cancer - Esaki - 2018 - Cancer Science - Wiley Online Library
A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity | PLOS ONE
Targeting glycosphingolipids for cancer immunotherapy
KAPAG collection – KAPAG Board + Paper
Monoclonal antibody therapies for high risk neuroblastoma | BTT
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells | Journal for ImmunoTherapy of Cancer
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells | Journal for ImmunoTherapy of Cancer
Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma | Science Translational Medicine
STARCOLOR MIRABELL™ GD2
Frontiers | CAR T Cell Therapy for Neuroblastoma
